Up To 50 SAR OFF Your First Order Use Code : APP50 | Get Free Delivery With No Minimum Order

Frequently bought together
AVOCOM-M CREAM 30G
- Sku : I-016215
Key features
AVOCOM-M Cream 30 g is a topical cream containing miconazole nitrate 2% and mometasone furoate 0.1%. Miconazole inhibits fungal 14-α-demethylase, impairing ergosterol synthesis and disrupting the fungal cell membrane, while mometasone binds glucocorticoid receptors to downregulate inflammatory mediator transcription, producing anti-inflammatory, antipruritic and vasoconstrictive effects. It is indicated for topical treatment of inflammatory superficial fungal infections, including dermatophyte tinea (tinea corporis, cruris and pedis) and cutaneous candidiasis, where concomitant anti-inflammatory therapy is required. Available by prescription in a 30 g cream.- Brand: AVOCOM
- Active Ingredient: MICONAZOLE NITRATE 2%, MOMETASONE FUROATE 0.1%
- Strength: 2,0.1%
- Dosage Form: Cream
- Pack Size: 30 g
- Route: Topical
- Prescription Status: Prescription
- Therapeutic Class: Dermatological
- Pharmacological Group: Antifungals (Topical)
- Drug Class: Topical imidazole antifungal (miconazole) + topical corticosteroid (mometasone; medium potency) combination.
- Manufacturer: (Avalon Pharma) Middle East Pharmaceutical Industries Co. Ltd
- Country of Origin: Saudi Arabia
- SFDA Registration No.: 2004257238
- Shelf Life: 24 months
- Storage: store below 30°c
- Skin Condition: Fungal
- Steroid Potency: Potent
Frequently bought together
Indications
Approved Uses
Topical treatment of inflammatory superficial fungal infections (dermatophyte tinea such as tinea corporis/cruris/pedis and cutaneous candidiasis) where concomitant anti-inflammatory therapy is indicated.
Dosage & Administration
Dosing by Condition
Inflammatory tinea corporis/cruris: apply a thin layer once daily for ~2 weeks (may extend up to 2-4 weeks if needed); tinea pedis: once daily for ~4 weeks; cutaneous candidiasis: once daily for ~2 weeks (up to 2-4 weeks based on response).
Initial Dose
Apply a thin layer to the affected area and immediate surrounding skin once daily
Maintenance Dose
Not intended for long-term maintenance therapy.
Maximum Dose
Apply a thin layer to affected skin only, typically once daily; avoid large surface areas and occlusion; do not use longer than 2 weeks (up to 3 weeks in some guidance) unless directed by a clinician.
Dose Adjustment Notes
No renal/hepatic dose adjustment is generally required with topical use; however, limit duration/area, avoid occlusion, and reassess if not improving (typically within ~2 weeks) to minimize systemic corticosteroid absorption and inappropriate prolonged steroid use.
How to Take
Clean and dry the affected area, then apply a thin layer to the affected skin (and a small margin of surrounding skin) and rub in gently; wash hands after application; avoid eyes/mucosa and do not use occlusive dressings unless directed.
Side Effects
Common Side Effects
Application-site burning, stinging, pruritus/itching, erythema/redness, irritation, dryness; less commonly peeling and folliculitis.
Safety & Warnings
Contraindications
Hypersensitivity to miconazole, mometasone, or any excipient; viral skin infections (e.g., herpes simplex, varicella); cutaneous tuberculosis; rosacea; perioral dermatitis; acne vulgaris; avoid ophthalmic use.
Warnings & Precautions
External use only; avoid eyes/face and do not use periocularly; avoid prolonged use, large areas, or occlusive dressings; stop and reassess if irritation/sensitization occurs or if infection worsens/no improvement; avoid use in diaper area unless specifically directed; treat confirmed fungal infection and avoid use on untreated bacterial/viral infections.
Driving Warning
Safe
Drug Interactions
Drug Interactions
Warfarin/other coumarin anticoagulants (topical miconazole may increase INR, especially with large-area/occlusive use); strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) may increase systemic corticosteroid effects if absorption occurs; additive effects with other topical/systemic corticosteroids on large areas/occlusion.
Food Interaction
No restriction
Alcohol Interaction
Safe
Special Populations
Pregnancy
Consult Doctor
Breastfeeding
Caution
Elderly
Standard adult dosing; use with caution due to increased risk of skin atrophy with corticosteroid component in elderly patients with thinner skin
Kidney Impairment
No adjustment needed
Liver Impairment
No dose adjustment is required for topical use.
Storage & Patient Advice
Missed Dose
Apply when remembered; if it is close to the next scheduled application, skip the missed dose and resume the regular schedule; do not apply extra to make up for a missed dose.
Monitoring Requirements
Short courses on limited areas: no routine labs; monitor clinically for local adverse effects (irritation, skin atrophy/striae, secondary infection) and treatment response; with prolonged/extensive use, occlusion, or pediatric use: monitor for HPA-axis suppression and systemic corticosteroid effects.
Pharmacology
Mechanism of Action
Miconazole inhibits fungal 14-α-demethylase (CYP450-dependent), reducing ergosterol synthesis and disrupting the fungal cell membrane; mometasone binds glucocorticoid receptors to downregulate inflammatory mediator transcription, producing anti-inflammatory, antipruritic, and vasoconstrictive effects.
Half-Life
Topical half-life is not well-defined because systemic exposure is minimal; when systemically available, mometasone furoate has an elimination half-life around ~5-6 hours, while miconazole’s systemic half-life is variable by route/formulation and is not clinically meaningful for topical therapy.
Bioavailability
Systemic absorption is minimal with topical use on intact skin: miconazole is typically <1% absorbed; mometasone furoate is low (about ~0.4% from cream and ~0.7% from ointment in studies), but increases with damaged skin, large surface area, prolonged use, or occlusion.
Metabolism
If absorbed systemically: mometasone furoate is extensively metabolized in the liver primarily via CYP3A4; miconazole is also hepatically metabolized and is a clinically relevant CYP inhibitor (notably CYP3A4/2C9) when systemic exposure occurs.
Product Information
Available Dosage Forms
Cream (30 g tube).
Composition per Dose
Per gram of cream: Miconazole nitrate 20 mg (2%) + Mometasone furoate 1 mg (0.1%)
Skin Condition
Fungal
Steroid Potency
Potent
Legal Disclaimer - Al Mujtama Pharmacy The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment. Al Mujtama Pharmacy assumes no legal or medical liability for: Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist Any discrepancy between the information provided and the product's package insert or SFDA guidelines Any misuse of medication resulting from personal interpretation of the content displayed Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication. By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation. Your health is a trust - always consult your doctor first.-1744229570.gif)















